Clinical trials
Other Solid Tumors clinical trials
Below are recruiting other solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,667 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT05857332RecruitingPhase 1
Testing a new drug for CLDN18.2-positive solid tumors
This Phase 1 study tests SG1906, a new investigational drug, in people with certain advanced solid tumors that test positive for CLDN18.2. The goal is to see whether the drug is safe and to learn how well it may work in shrinking tumors or controlling the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05536141RecruitingPhase 1
Study of AB521 for kidney cancer and other solid tumors
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
Birmingham, AlabamaAges 18 years+ - NCT05458219RecruitingPhase 1
Testing an antibody-drug treatment for solid tumors
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
Austin, TexasAges 18 years+ - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07712029RecruitingPhase 2
A new drug combo for EGFR positive advanced solid tumors
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07492680RecruitingPhase 2
Study of BMS-986504 for solid tumors with MTAP deletion
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
San Francisco, CaliforniaAges 18 years+ - NCT07357636Recruiting
Immune therapy side effects study for solid tumors
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
Fuzhou, FujianAges 18 years+ - NCT07232524RecruitingPhase 1
BL-M24D1 for advanced head and neck and other solid tumors
This study tests a new drug called BL-M24D1 in people with head and neck cancer or other solid tumors that have spread or cannot be surgically removed. The goal is to see if the drug is safe and can help shrink tumors.
Chengdu, SichuanAges 18 years+ - NCT07190833RecruitingPhase 1
Study of a cancer-killing virus injection for solid tumors
This early-phase trial tests a cancer-killing virus (OTS-412) that is injected directly into tumors. It is for people with solid tumors that have not responded to standard treatments, including immunotherapy. The goal is to see if the virus can shrink or control the injected tumors.
BusanAges 19 years+ - NCT07189949RecruitingPhase 1
Study of HRS-2329 for advanced solid tumors with RAS changes
This trial tests a new drug, HRS-2329, for people with advanced solid tumors that have a RAS mutation or amplification and haven't responded to standard treatments. It aims to see if the drug can help shrink or control the tumors.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07142980RecruitingPhase 1
Study of HRS-7172 for advanced solid tumors with RAS mutations
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06970795RecruitingPhase 1
Study of SYS6040 for advanced solid tumors
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Changchuan, JilinAges 18 years+ - NCT05541822RecruitingPhase 2
Study drug for lung cancer with specific c-MET changes
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Lake City, FloridaAges 18 years+ - NCT07056556RecruitingPhase 1
Study of BL-M09D1 for advanced lung and other solid tumors
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07060989RecruitingPhase 1/Phase 2
Study of NTS071 for advanced solid tumors with TP53 Y220C mutation
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
Houston, TexasAges 18 years+ - NCT06410131RecruitingPhase 1
Safety study of FTL008.16 for advanced solid tumors
This trial tests an investigational drug called FTL008.16 for people with advanced solid tumors that may carry a protein called 5T4. The main goal is to see if the drug is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–75 - NCT06761417RecruitingPhase 2
Liposomal mitoxantrone for children and young adults with relapsed solid tumors
This trial tests a new form of chemotherapy (liposomal mitoxantrone) for children, adolescents, and young adults whose solid tumors have come back or not responded to treatment. The goal is to see if this combination regimen can help shrink tumors.
BeijingAges 6–24 - NCT06375564RecruitingPhase 1
A new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
Xiamen, FujianAges 18–90 - NCT06672523RecruitingPhase 1
Study of a new drug for advanced solid tumors with MTAP deletion
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
BudapestAges 18 years+ - NCT06612840RecruitingPhase 1
A study of GNC-077 for advanced lung cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced non-small cell lung cancer or other solid tumors that have spread. It aims to see if the drug is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06469008RecruitingPhase 1
Study of BL-B16D1 for advanced head and neck cancer and other solid tumors
This study tests a new drug, BL-B16D1, for people with advanced head and neck cancer or other solid tumors that have not been helped by standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other solid tumors?
- Yes. Clin2 currently lists 1,667 recruiting other solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.